E-resources
Peer reviewed
-
Günther, Gunar; Guglielmetti, Lorenzo; Kherabi, Yousra; Duarte, Raquel; Lange, Christoph; Adamides, Tonia; Akkerman, Onno; Andersen, Aase Bengaard; Bakos, Ágnes; Bjarnason, Agnar; Bruchfeld, Judith; Chesov, Dumitru; Codecasa, Luigi Ruffo; Cirillo, Daniela; Danilovits, Manfred; Davidavičienė, Edita; Duarte, Raquel; De Souza Galvão, Maria Luiza; Garnier, Sandrine; Gjocaj, Majlinda; Günther, Gunar; Ibraim, Elmira; Kappnik, Michael; Khachatryan, Naira; Klimuk, Dzmitry; Kuksa, Liga; Jachym, Mathilde Frechet; Josefsdottir, Kamilla; Kaluzhenina, Anna; Lange, Christoph; Mack, Ulrich; Makek, Mateja Jankovic; Manika, Katerina; Mclaughlin, Anne-Marie; Mema, Donika; Mengshoel, Anne Torunn; Muylle, Inge; Nanovic, Zorica; Özkara, Şeref; Perl, Sivan; Pesut, Dragica; Pierdou, Despo; Ryskulov, Galym; Skowroński, Marcin; Solovic, Ivan; Sukholytka, Mariia; Svetina, Petra; Terleeva, Yana; Tiberi, Simon; Togonidze, Tamara; Torri, Stefania; Turaev, Laziz; Usmanova, Ruzilya; Wirtz, Gil; Vasankari, Tuula; Zhdanova, Elena
Clinical microbiology and infection, 2024-Mar-13Journal Article
Multidrug-resistant/Rifampicin-resistant tuberculosis (TB) is a major obstacle to successful TB control. The recommendation by the World Health Organization to use bedaquiline, pretomanid, linezolid and moxifloxacin (BPaL(M)) for 6 months, based on results of three trials with high efficacy and low toxicity, has revolutionized treatment options. In this study, representatives of the Tuberculosis Network European Trialsgroup (TBnet) in 44/54 countries of the WHO Europe region document the availability of the medicines and drug susceptibility testing (DST) of the BPaL(M) regimen through a structured questionnaire between September to November 2023. 24/44 (54.5%), 42/44 (95.5%), 43/44 (97.7%), and 43/44 (97.7%) had access to pretomanid, bedaquiline, linezolid, and moxifloxacin, respectively. Overall, 23/44 (52.3%) had access to all the drugs composing the BPaL(M) regimen. 7/44 (15.9%), 28/44 (63.6%), 34/44 (77.3%) and 36/44 (81.8%) had access to DST for pretomanid, bedaquiline, linezolid and moxifloxacin, respectively. DST was available for all medicines composing the BPaL(M) regimen in 6/44 (13.6%) countries. Only in about half of the countries participating in the survey clinicians have access to all the BPaL(M) regimen drugs. In less than a fifth of countries, a complete DST is possible. Rapid scale up of DST capacity to prevent unnoticed spread of drug resistance and equal access to new regimens are urgently needed in Europe.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.